Media Releases

Maddocks advises ANSTO on radiopharma licence agreement with ITM

• 08 March 2022 • 1 min read
  • Share

Maddocks has advised the Australian Nuclear Science and Technology Organisation (ANSTO) on a new long-term IP and technology licence agreement with leading German radiopharmaceutical biotech company ITM Isotope Technologies Munich SE (ITM).

Under the agreement, ANSTO will continue to produce medical radioisotope n.c.a. Lutetium-177 (n.c.a. 177Lu) for the Australian and New Zealand markets using ITM’s production technology. N.c.a. 177Lu is used as a radiopharmaceutical precursor in Targeted Radionuclide Therapy, a novel treatment regimen in precision oncology.

The continuation of ANSTO’s long-standing partnership with ITM is significant as it allows local manufacturing to continue to support growing demand of patients in the Australia-New Zealand region.

The Maddocks team was led by IP and life sciences partner Ben Miller, with assistance from lawyer Sophie Vo and our IP and pharma regulatory team.

About Maddocks

Maddocks is a proudly independent Australian law firm that works closely with corporations, businesses and governments throughout Australia and internationally. We advise national and international clients across the education, government, healthcare, infrastructure and technology sectors, from our Canberra, Melbourne and Sydney offices. Our specialist expertise includes intellectual property, life sciences, dispute resolution and litigation, employment and safety, financial services, franchising and insolvency.

For more information:

Jason Silverii
Communications Manager
Tel: 03 9258 3509
Mobile: 0407 618 058
jason.silverii@maddocks.com.au

  • Share

Keep up to date with our legal insights and events

Sign up

Related capabilities


Corporate & Commercial

Related sectors


Healthcare

Related services


Intellectual Property

Related articles

Online Access